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EDITORIAL COMMENT
Stem Cell Therapy
for Myocardial Repair
Is it Arrhythmogenic?*
Raj R. Makkar, MD,† Michael Lill, MD,‡
Peng-Sheng Chen, MD, FACC†
Los Angeles, California
Transplantation of both skeletal myoblasts and stem cells
into the region of infarcted myocardium results in improved
myocardial function in both the murine and porcine infarct
models. Intravenous injection of stem cells and bone mar-
row stimulating cytokines also improves cardiac function
(1–4). The optimal cell type and dose, delivery route,
delivery catheter, and the timing of cell injection are still
being defined. In order for cell therapy to be widely
clinically applicable, the optimal cell has to be compatible
both mechanically and electrically with the host myocar-
dium. In this issue of the Journal, Smits et al. (5) extend the
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observations to humans, confirming the previous observa-
tions of Menasche et al. (6,7) that myoblast transplantation
improves global and regional left ventricular function late
after myocardial infarction. This procedure has clinical
application because cells could be delivered by transendo-
cardial injection in the catheterization laboratory.
Nevertheless, the study also exposes a potential serious
limitation of both myoblast and stem cell therapy. In the
current study (5), one of the five patients had sustained
episodes of ventricular tachycardia and required implantable
cardioverter-defibrillator (ICD) placement. The investiga-
tors also describe a subsequent unpublished experience of
two sudden deaths and three serious ventricular arrhythmias
in eight additional patients. These data seem to correspond
to the Menasche et al. (6,7) experience in which 4 of 10
patients required ICD implantation for ventricular arrhyth-
mias after open chest autologous myoblast transplantation.
Although, it remains possible that these arrhythmias reflect
the natural history of myocardial infarction rather than the
introduction of the new cells, it seems clear that we must
consider the potential mechanisms of arrhythmia and strat-
egies to control or eliminate them.
Proarrhythmia after stem cell therapy might be attributed
to one or more of the following reasons: 1) heterogeneity of
action potentials between the native and the transplanted
stem cells; 2) intrinsic arrhythmic potential of injected cells;
3) increased nerve sprouting induced by stem cell injection;
and 4) local injury or edema induced by intramyocardial
injection.
ELECTROPHYSIOLOGIC HETEROGENEITY
Normal cardiac cells exhibit significant transmural hetero-
geneity of action potential duration (8). A delicate balance
has to be maintained to prevent arrhythmia. When abnor-
mal shortening or prolongation of action potential duration
in some, but not all, of the myocardial cells, disturbs this
balance, the incidence of arrhythmia increases. Brugada
syndrome and long QT syndrome are two examples of
increased arrhythmogenesis due to increased transmural
dispersion of repolarization (9). In diseased ventricles, the
electrophysiologic remodeling alters the ion channel activity
(10), which can increase the dispersion of repolarization
even before stem cell transplantation. The transplanted cells
also might further increase the electrophysiologic heteroge-
neity.
Leobon et al. (11) used intracellular recordings coupled
with video and fluorescence microscopy to study the con-
tractile and intrinsic membrane properties of labeled myo-
blasts, transplanted into infarcted rat myocardium. The
grafted myoblasts differentiated into hyperexcitable myo-
tubes with a contractile activity fully independent of neigh-
boring cardiomyocytes. No structural connection was ob-
served between myotubes or between myotubes and host
cardiomyocytes when Alexa Fluor (Molecular Probes), a
connexin permeant dye, was injected in myotubes. In
contrast, dye coupling was extensively observed between
cardiomyocytes. The action potentials evoked intracellularly
in myotubes were accompanied by myotube contractions,
but these contractions did not spread to neighboring cardi-
omyocytes. Electrical stimulation of myotubes evoked a
slow voltage-dependent discharge with superimposed bursts
of action potentials that were similar to thalamic neuron
discharges rather than cardiomyocyte activity. These multi-
ple action potentials clearly carry the potential for inducing
cardiac hyperexcitability, even in the absence of direct
electromechanical coupling, through electrotonic interac-
tion.
This mechanism may be specific for transplanted myo-
blasts, because embryonic stem cells have been reported to
differentiate into a spontaneously contracting functional
syncytium with gap junctions distributed along the cell
borders (12). Microelectrode array mapping of this early-
stage cardiac tissue demonstrated synchronized action po-
tential propagation with stable focal activation and conduc-
tion properties. Nonetheless, the conduction-velocity in the
stem cells was less than that of intact human heart. The
lower gap junction size and density, the significant presence
of connexin 45, and less developed ionic channel machinery
in early-stage cardiomyocytes may result in slower conduc-
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tion velocities and a potential substrate for re-entrant
arrhythmias.
INTRINSIC ARRHYTHMOGENICITY OF
TRANSPLANTED CELLS
Zhang et al. (13) studied the intrinsic arrhythmogenic
properties of cardiomyocytes derived from mouse pluripo-
tent embryonic stem cells in vitro using the whole-cell
patch-clamp method. Cultured stem cell-derived cardiomy-
ocytes exhibited morphologic heterogeneity of action po-
tentials, many of which had reduced maximum upstroke
velocity, prolonged durations, and spontaneous electrical
activity in culture. These electrophysiologic changes were
accompanied by frequent triggered activity and both early
and delayed after depolarization with and without pharma-
cologic enhancement. Thus, cultured stem cells exhibit all of
the three arrhythmogenic mechanisms: 1) re-entry, 2) au-
tomaticity, and 3) triggered activity.
NERVE SPROUTING
Sympathetic nerve activation exerts significant effects on
electrophysiologic properties such as automaticity, triggered
activity, refractoriness, and conduction velocity of myocar-
dial cells (14–16). Consequently, an increased and hetero-
geneous cardiac innervation might amplify the spatial inho-
mogeneity of electrophysiologic properties and facilitate the
initiation of ventricular arrhythmia (17,18). We have dem-
onstrated that mesenchymal stem cell injection to the swine
myocardium induces increased sympathetic nerve density
throughout the ventricles (19). Thus, although increased
sympathetic innervation could increase contractility and
ejection fraction of the treated ventricles, it might also
induce ventricular arrhythmias by increasing dispersion of
repolarization and triggered arrhythmias (20,21), particu-
larly in a damaged ventricle with abnormal ion channel
activity caused by electrical remodeling.
LOCAL INJURY
Most cases of arrhythmias in the early clinical trials have
been associated with intramyocardial rather than intracoro-
nary injection. Tissue injury could be responsible for ar-
rhythmogenesis after intramyocardial injection. On the
other hand, no increase in ventricular arrhythmias has been
reported after therapies such as direct laser transmyocardial
revascularization that cause local tissue damage and scarring.
Nonetheless, local injection also induces a highly uneven
distribution of cells, at least early after injection, which
increases electrophysiologic heterogeneity.
The nature of the injected cell may have the most impact
on arrhythmogenesis after transplantation. Myoblasts and
stem cells differ in their inherent electrophysiologic proper-
ties and in their ability to couple electromechanically both
among themselves and with host cardiomyocytes. Limited
clinical data available thus far (22–27) (Table 1) suggest that
arrhythmias are more likely to occur after myoblast than
after stem cell transplantation. Finally, limited clinical
experience suggests that proarrhythmic effects of cell ther-
apy may be transient. Nonetheless, because the occurrence
of cardiac arrhythmia is highly unpredictable, long-term
follow-up studies of cell transplant recipients would seem to
be essential for understanding the natural course of myoblast
and stem cell induced arrhythmogenesis.
Future pre-clinical and clinical studies will determine the
most effective and safe cell type for myocardial repair and
the clinical significance of cell therapy-induced arrhythmias.
In the interim, it is prudent to restrict the use of myoblast
transplantation to patients with an implanted cardiac defi-
brillator. The monitoring function of the ICD can provide
investigators with accurate statistics on the incidence, types,
and time course of arrhythmias associated with cell trans-
plantation. These data will be critical for evaluation of the
arrhythmia risks associated with this new option of treating
congestive heart failure. Although stem cell therapy has not
been reported to induce early cardiac arrhythmias, investi-
gators need to be aware of the potential risk and include
careful long-term follow-up for arrhythmia detection in
their clinical trials.
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Table 1. Arrhythmias After Stem Cell Therapy
Study (Ref.) Cell Type Route n Death Arrhythmias ICD
Menasche et al. (6,7) Myoblasts Epicardial 10 0 4 (VT) 4
Smits et al. (5)* Myoblasts Endocardial 13 2 4 (VT) 2
Strauer et al. (22) BM cells Intracoronary 10 0 0 0
Assmus et al. (23) BM cells Intracoronary 19 0 0 0
Stamm et al. (24) BM cells Epicardial 6 0 2 (SV) 0
Perin et al. (25) BM cells Endocardial 14 1 (SCD) 0 0
Fuchs et al. (26) BM cells Endocardial 10 0 0 0
Tse et al. (27) BM cells Endocardial 8 0 0 0
References 25, 26, and 27 were studies primarily directed towards angiogenesis rather than myogenesis. *The “n” in the Smits
et al. study includes eight patients described in the “Discussion” section who received catheter-based myoblast transplantation
in addition to the five patients in the original study.
BM  bone marrow-derived; ICD  implantable cardioverter-defibrillator; SCD  sudden cardiac death; SV 
supraventricular arrhythmias; VT  ventricular tachycardia.
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